Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Now Covered by Analysts at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $62.00 price target on the stock.

A number of other equities research analysts have also weighed in on the stock. The Goldman Sachs Group upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus target price of $53.71.

Kiniksa Pharmaceuticals International Trading Up 3.9%

NASDAQ KNSA opened at $47.17 on Thursday. The company has a market cap of $3.58 billion, a P/E ratio of 104.82 and a beta of 0.06. The company has a fifty day simple moving average of $42.59 and a 200 day simple moving average of $39.27. Kiniksa Pharmaceuticals International has a 12-month low of $18.25 and a 12-month high of $47.51.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the sale, the chief financial officer directly owned 12,086 shares in the company, valued at approximately $523,082.08. This trade represents a 59.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the transaction, the chief operating officer directly owned 16,666 shares in the company, valued at approximately $692,638.96. This represents a 41.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 123,823 shares of company stock valued at $5,244,967. 53.48% of the stock is owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of large investors have recently added to or reduced their stakes in the stock. Mark Sheptoff Financial Planning LLC raised its position in Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after acquiring an additional 250 shares during the period. Mariner LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 2.0% in the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after purchasing an additional 266 shares during the period. Virtus Investment Advisers LLC lifted its stake in Kiniksa Pharmaceuticals International by 2.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after purchasing an additional 406 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Kiniksa Pharmaceuticals International by 7.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after purchasing an additional 508 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.